Investment
Features
FeesSafety
Academy
More
Pluang+

Compare HP Inc (HPQ) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance

Recursion Pharmaceuticals IncTrade

Price performance (Past 24H)

Key statistics

HP Inc vs Recursion Pharmaceuticals Inc — how do they compare? HP Inc trades at $29.2 (market cap $26.59B), while Recursion Pharmaceuticals Inc trades at $3.29 (market cap $1.81B). The key difference: HP Inc is far larger — about 14.7× Recursion Pharmaceuticals Inc's market cap, and HP Inc pays a 4.13% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.

HPQRXRX
Market Cap
$26.59B$1.81B
Sector
TechnologyHealth
52-Week High
$30.05$6.79
52-Week Low
$18.20$2.84
Enterprise Value
$33.75B$1.33B
Dividend Yield
4.13%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

HP Inc

HPQ trades at $28.96, down 2.82% today, with a bullish technical signal from moving averages and strong earnings beats in recent quarters. Revenue for 2025 reached $55.3 billion, with a net income margin of 4.45%, while valuation metrics like a P/E of 10.77 and P/S of 0.48 suggest potential undervaluation. Recent news highlights AI-driven cost savings and a profitable upgrade cycle, with Q2 FY2026 revenue up 9% year-over-year.

The outlook is mixed; HPQ benefits from solid cash flow and dividend yields near 4%, but faces risks from PC market declines and competitive pressures. Analyst consensus is cautious with a hold-heavy rating, and the stock trades above the consensus price target of $22, indicating limited upside. Investors should weigh steady profitability against industry headwinds and valuation constraints.

Recursion Pharmaceuticals Inc

RXRX trades at $3.29, showing no change in the last session. The stock exhibits a bullish technical signal with moving averages supporting an uptrend, though RSI levels suggest potential overbought conditions. Fundamentally, the company reported a Q2 2026 loss of $0.25 per share, missing estimates, with revenues declining year-over-year. Recent news highlights ongoing investor conferences and partnership advancements, such as Genentech optioning a neuroscience target, but profitability remains a challenge with a net income margin of -961.97% for 2026.

The outlook for RXRX is mixed, with analyst consensus leaning hold (60%) due to high cash burn and unproven commercial scalability. Investment opportunity lies in its AI-driven drug discovery platform and partnerships, but risks include sustained losses, competitive pressures, and reliance on milestone payments. The stock's trajectory hinges on pipeline success and cost management improvements.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About HP Inc

HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.

Read more on HPQ

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.

Read more on RXRX